Paper Details
- Home
- Paper Details
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Author: BureIrina Vladimirovna, KibitovAlexander Olegovitch, KibitovAndrey Alexandrovitch, KiryanovaElena Mikhaylovna, SalnikovaLudmila Ivanovna, ShmuklerAlexander Borisovitch
Original Abstract of the Article :
Extrapyramidal symptoms (EPS) are one of the most prominent side effects of haloperidol. Variability of EPS severity may be associated with the genetic factors, affecting both haloperidol pharmacokinetics (e.g., CYP2D6) and pharmacodynamics (e.g., DRD2, ANKK1). We conducted a 3-week prospective stud...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1515/dmpt-2022-0143
データ提供：米国国立医学図書館（NLM）
The ANKK1/DRD2 TaqIA Polymorphism and Haloperidol Side Effects: Exploring the Desert of Genetics
Haloperidol, a medication used to treat schizophrenia, can sometimes cause extrapyramidal side effects (EPS), like unwelcome sandstorms in the desert of treatment. This study investigates the role of genetic factors in influencing the severity of these side effects, searching for clues in the desert of our genes.
The researchers, like skilled geneticists, explored the association between the ANKK1/DRD2 TaqIA polymorphism, a genetic variation, and the severity of EPS in patients taking haloperidol. Their findings, like a hidden oasis, suggest that this polymorphism might play a role in determining the likelihood of experiencing EPS, particularly in individuals with a specific CYP2D6 metabolic phenotype.
Navigating the Genetic Desert of Medication Response
This research highlights the importance of considering genetic factors when prescribing medications. It emphasizes the need for personalized approaches to treatment, taking into account individual genetic variations and their potential impact on drug response.
Tailoring Treatment in the Desert
This study suggests that understanding genetic predispositions to side effects can help improve patient outcomes. It emphasizes the need for continued research and the development of personalized medicine approaches to optimize treatment strategies and minimize unwanted side effects.
Dr.Camel's Conclusion
The desert of medication response can be complex and unpredictable. This study reminds us that our genes can influence how we react to certain drugs, highlighting the importance of personalized care and considering genetic factors in treatment decisions. As we continue to explore the genetic landscape of health and disease, we can develop more precise and effective approaches to care.
Date :
- Date Completed 2023-06-16
- Date Revised 2023-06-16
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.